This website uses cookies to store user session information. By using our website you consent to our terms of use. Read more
I agree

Radko Avi

https://www.etis.ee/CV/Radko_Avi/eng
15.10.1980
737 4177
radko.avi@ut.ee

Career

Institutions and positions
01.03.2018–...   
University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Senior Research Fellow in Medical Virology (1,00)
01.01.2016–...   
University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Research Fellow in Medical Virology (1,00)
01.01.2010–...   
University of Tartu, Medical Faculty, Department of Microbiology, researcher of medical virology (1.00)
01.09.2015–31.12.2015   
University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow in Medical Virology (1,00)
01.02.2013–31.08.2015   
University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow in Medical Virology (1,00)
01.02.2010–31.01.2013   
University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow in Medical Virology (1,00)
01.02.2007–31.01.2010   
University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow (1,00)
01.10.2006–31.01.2007   
University of Tartu, Faculty of Medicine, Department of Microbiology, Research Fellow extraordinarius (1,00)
01.04.2005–30.09.2006   
University of Tartu, Faculty of Medicine, Department of Microbiology, Laboratory Assistant (0,75)
 
 
Education
2006–2011   
University of Tartu, Medical Virology, Ph.D
2004–2006   
University of Tartu, Biomedicine, M.Sc
2000–2004   
University of Tartu, Genetechnology, B.Sc

Qualifications

Academic degrees
Radko Avi, Doctor's Degree, 2011, (sup) Irja Lutsar, Natural polymorphisms and transmitted drug resistance in Estonian HIV-1 CRF06_cpx and its recombinant viruses, University of Tartu.
Radko Avi, Research Master's Degree, 2006, (sup) Irja Lutsar, Looduslikud resistentsusmutatsioonid Eestis levivatel HI-viirustel, University of Tartu, Faculty of Medicine.
 
 

Completed projects

Dissertations under supervision

Supervised dissertations

Publications

1.1. Scholarly articles indexed by Web of Science Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index and/or indexed by Scopus (excluding chapters in books)
 
Soodla, Pilleriin; Huik, Kristi; Pauskar, Merit; Cuypers, Lize; Van Laethem, Kristel; Rajasaar, Heli; Kallas, Eveli; Lepa, Helen; Velts-Lindh, Anna; Jõgeda, Ene-Ly; Lutsar, Irja; Avi, Radko (2019). Stable level of HIV transmitted drug resistance in Estonia despite significant scale-up of antiretroviral therapy. Infection, Genetics and Evolution, 75, 103901−103901.10.1016/j.meegid.2019.05.019.
 
Huik, Kristi; Soodla, Pilleriin; Pauskar, Merit; Owen, S. Michele; Luo, Wei; Murphy, Gary; Jogeda, Ene-Ly; Kallas, Eveli; Rajasaar, Heli; Avi, Radko; Masciotra, Silvina; Lutsar, Irja; Del Amo, Julia; Meyer, Laurence; Bucher, Heiner C.; Chene, Genevieve; Hamouda, Osamah; Pillay, Deenan; Prins, Maria; Rosinska, Magda ... Scott, Martin (2019). The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx. PLOS ONE, 14 (5), ARTN e0217048.10.1371/journal.pone.0217048.
 
Soodla, Pilleriin; Huik, Kristi; Pauskar, Merit; Cuypers, Lize; Van Laethem, Kristel; Rajasaar, Heli; Kallas, Eveli; Lepa, Helen; Velts-Lindh, Anna; Jõgeda, Ene-Ly; Lutsar, Irja; Avi, Radko; (2019). Stable level of HIV transmitted drug resistance in Estonia despite significant scale-up of antiretroviral therapy. Infection, Genetics and Evolution, 75, 103901.10.1016/j.meegid.2019.05.019.
 
Jõgeda, E-L; Avi, R; Pauskar, M; Kallas, E; Karki, T; Des Jarlais, D; Uusküla, A; Toompere, K; Lutsar, I; Huik, K (2018). Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. Journal of Medical Virology, 90 (11), 1779−1783.10.1002/jmv.25258.
 
Jogeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Karki, Tonis; Jarlais, Don Des; Uuskula, Anneli; Lutsar, Irja; Avi, Radko (2017). Prevalence and Genotypes of GBV-C and Its Associations With HIV Infection Among Persons Who Inject Drugs in Eastern Europe. Journal of Medical Virology, 89 (4), 632−638.10.1002/jmv.24683.
 
Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLOS ONE, 11 (6), e0156850−e0156850.10.1371/journal.pone.0156850.
 
Avi, Radko; Pauskar, Merit; Karki, Tõnis; Kallas, Eveli; Jõgeda, Ene-Ly; Margus, Tõnu; Huik, Kristi; Lutsar, Irja (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology, 88 (3), 448−454.10.1002/jmv.24361.
 
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi (2016). Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection, Genetics and Evolution, 43, 83−85.10.1016/j.meegid.2016.05.022.
 
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 205 (3), 231−239.10.1007/s00430-015-0444-8.
 
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral immunology, 0−0.vim.2016.0057.
 
Soodla, P.; Rajasaar, H.; Avi, R.; Zilmer, K.; Kink, K.; Novikova, L.; Huik, K.; Maimets, M.; Lutsar, I. (2015). Design and structure of the Estonian HIV Cohort Study (E-HIV). Infectious Diseases, 47 (11), 768−675.10.3109/23744235.2015.1061203.
 
Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda, E.-L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection, Genetics and Evolution, 30, 175−180.10.1016/j.meegid.2014.12.023.
 
Rhee, S.-Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M.-L. ... Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLOS Medicine, 12 (4), e1001810.10.1371/journal.pmed.1001810.
 
Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66 (3), 239−244.10.1097/QAI.0000000000000127.
 
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Kallas, E; Jõgeda, EL; Krispin, T; Lutsar, I (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. Aids Research and Human Retroviruses, 30 (3), 278−283.10.1089/aid.2012.0357.
 
Huik, K; Avi, R; Pauskar, M; Kallas, E; Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection, Genetics and Evolution, 20, 78−82.10.1016/j.meegid.2013.08.008.
 
Huik, K; Avi, R; Carrillo, A; Harper, N; Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLOS ONE, 8 (7), e70561.10.1371/journal.pone.0070561.
 
Laisaar, K.-T.; Avi, R.; Dehovitz, J.; Uusküla, A. (2011). Estonia at the Threshold of the Fourth Decade of the AIDS Era in Europe. Aids Research and Human Retroviruses, 27 (8), 841−851.10.1089/aid.2010.0223.
 
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2011). Emerging Transmitted Drug Resistance in Treatment Naive Human Immunodeficiency Virus - 1 CRF06_cpx Infected Patients in Estonia. Scandinavian Journal of Infectious Diseases, 43 (2), 122−128.
 
Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2010). Characterization of Integrase Region Polymorphisms in HIV-1 CRF06_cpx Viruses in Treatment Naïve Patients in Estonia. Aids Research and Human Retroviruses, 26 (10), 1109−1113.10.1089/aid.2010.0097.
 
Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730−739.
 
Avi, R; Huik, K; Sadam, M; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2009). Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus-1 CRF06_cpx in Treatment-Naive Patients in Estonia. Journal of Medical Virology, 81 (6), 953−958.10.1002/jmv.21482.
2.4. University textbooks
 
Lutsar, Irja; Mändar, Reet; Mikelsaar, Marika; Karki, Tõnis; Brilene, Tatjana; Kõljalg, Siiri; Meriste, Sirli; Sepp, Epp; Avi, Radko; Truusalu, Kai; Parm, Ülle (2017). Meditsiiniline Mikrobioloogia. Üldmikrobioloogia. Tartu: TÜ kirjastus.
3.1. Articles/chapters in books published by the publishers listed in Annex (including collections indexed by the Thomson Reuters Book Citation Index, Thomson Reuters Conference Proceedings Citation Index, Scopus)
 
Rätsep, M.; Hütt, P.; Avi, R.; Utt, M.; Songisepp, E. (2011). Antimicrobial properties of Lactobacillus plantarum Tensia (DSM 21380) and Inducia (DSM 21379). In: Mendez-Vilas, A. (Ed.). Science and Technology against Microbial Pathogens. Research, Development and Evaluation. (393−397).. World Scientific Publ Co Pte Ltd.
3.5. Articles/presentations published in local conference proceedings
 
Tamman, S; Denks, K; Huik, K; Parm, Ü; Avi, R; Lutsar, I. (2008). Klebsiella pneumoniae genotüpiseerimine multiensüüm-multipleks amplified fragmrnt length polymorphism PCR (AFLP-PCR) meetodil. Eesti Arst.
5.1. Conference abstracts indexed by Thomson Reuters Web of Science
 
Avi1, R.; Pauskar2, M.; Rajasaar3, H.; Kallas4, E.; Jogeda5, E.; Soodla6, P.; Lutsar7, I. (2017). VIROLOGICAL RESPONSE TO ANTIRETROVIRAL TREATMENT IN AN EASTERN EUROPEAN COHORT STUDY. CROI Foundation/IAS–USA,.
 
Denks, K.; Huik, K.; Avi, R.; Sadam, M.; Krispin, T.; Lutsar, I. (2007). GB virus C infection among HIV-positive patients in Estonia. International Journal of Antimicrobial Agents, 29 (3), S155−S155.
 
Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Paap, P.; Smidt, J.; Ainsalu, K.; Krispin, T.; Lutsar, I (2007). The coexistence of secondary PR mutations M36I, K20I and L63H predominates in CRF06_cpx and its next generation recombinant virusese circulating in Estonian treatment naive patients. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 29. S549−S549.
5.2. Conference abstracts that do not belong to section 5.1
 
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Jarlais, Don Des; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi; (2015). HTLV-1/2 is rare among Eastern-European intravenous drug users (IDUs). Retrovirology, 12, P79−P79.10.1186/1742-4690-12-S1-P79.
 
Avi, Radko; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Šmidt, Jelena; Novikova, Lilia; Semjonova, Svetlana; Lutsar, Irja. (2013). Substitutions in RNaseH and Connection domain of HIV-1 CRF06_cpx viruses in treatment naive and treatment experienced populations. 11th European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance; Rome; 20-22 March 2013. 35−35.
 
Jõgeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Krispin, Tõnu; Karki, Tõnis; Marsh, Kristina; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja. (2013). The prevalence of GBV-C and its associations with HIV infection among Estonian intravenous drug users. Reviews in Antiviral Therapy Infectious Diseases: 11th European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance; Rome; 20-22 March 2013. 46−47.
 
Avi, R.; Huik, K.; Pauskar, M., Lutsar, I.; Vandamme, A.; Abecasis, A. (2012). The population dynamics of the HIV-1 epidemic in Estonia through virus genetic analysis and national case recording. 17th International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology, 27-31 August 2012 Belgrade Serbia.
 
Uibopuu, H.; Huik, K.; Avi, R.; Pauskar, M.; Kallas, E.; Karki, T.; Krispin, T.; Kool, P.; Schmidt, J.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Lutsar, I. (2012). Viral tropism of HIV-1 CRF06_cpx and its association with CCR5 haplotypes. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.
 
Pauskar, M.; Avi, R.; Huik, K.; Ustina, V.; Jõgeda, E.; Kallas, E.; Karki, T.; Krispin, T.; Lutsar, I. (2012). Transmitted drug resistance is 4.5% in newly diagnosed mainly HIV-1 CRF06_cpx infected patients in Estonia in 2010. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.
 
Avi, R.; Huik, K.; Pauskar, M.; Kallas, E.; Karki, T.; Krispin, T.; Ainsalu, K.; Semjonova, S.; Kool, P.; Novikova, L.; Schmidt, J.; Lutsar, I. (2012). The pattern of drug resistance mutations in HIV-1 CRF06_cpx viruses failing the first-line NNRTI+2NRTI antiretroviral therapy. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.
 
Kallas, E.; Avi, R.; Huik, K.; Pauskar, M.; Ustina, V.; Karki, T.; Krispin, T.; Ainsalu, K.; Semjonova, S.; Kool, P.; Novikova, L.; Schmidt, J.; Lutsar, I. (2012). HIV Type-1 CRF06_cpx P(T/S)AP Late Domain duplications are outselected among treatment experienced compared to treatment naïve patients. Reviews in Antiviral Therapy & Infectious Diseases. ,.
 
Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Denks, K.; Krispin, T.; Ustina, V.; Rüütel, K.; Uusküla, A.; Murphy, G.; Lutsar, I. (2009). Performance of the BED-CEIA in population infected with HIV1 recombinant viruses CRF06cpx and CRF06A. Clinical Microbiology and Infection: 19th European Congress of Clinical Microbiology and Infectious Diseases Helsinki, Finland, 16 - 19 May 2009.
 
Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Albert, J.; Lutsar, I. (2008). Drug Resistance Mutations in HIV-1 CRF06_cpx Viruses Isolated from Treatment Naïve and Experienced Patients. European Journal of Medical Research: 19th European Students’ Conference; Berlin; 28 September - 3 October 2008.
 
Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Drug Resistance Mutations and Genetic Barrier for Drug Resistance Development in Estonian HIV-1 CRF06_cpx Integrase Sequences. 14th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology; Cape Town, South Africa; 1-5 September 2008.
 
Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Paap, P.; Ainsalu, K.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Natural polymorphisms associated with integrase inhibitor drug resistance in Estonian HIV-1 CRF06_cpx strains. 18th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19.04-22.04.2008.
 
Sadam, M.; Karki, T.; Huik, K.; Avi, R.; Rüütel, K.; Uusküla, A.; Lutsar, I (2008). CCL3L1 Variable Gene Copy Number Influence on the Susceptibility to HIV-1/AIDS Among Estonian Intravenous Drug User. The 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 03.02-06.02.2008.
24.03.2020

Radko Avi

https://www.etis.ee/CV/Radko_Avi/est
15.10.1980
737 4177
radko.avi@ut.ee

Teenistuskäik

Töökohad ja ametid
01.03.2018–...   
Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut, meditsiinilise viroloogia vanemteadur (1,00)
01.01.2016–...   
Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut, meditsiinilise viroloogia teadur (1,00)
01.01.2010–...   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, Meditsiinilise mikrobioloogia ja viroloogia õppetool; meditsiinilise viroloogia teadur (1.00)
01.09.2015–31.12.2015   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, meditsiinilise viroloogia teadur (1,00)
01.02.2013–31.08.2015   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, meditsiinilise viroloogia teadur (1,00)
01.02.2010–31.01.2013   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, meditsiinilise viroloogia teadur (1,00)
01.02.2007–31.01.2010   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, meditsiinilise viroloogia teadur (1,00)
01.10.2006–31.01.2007   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, erakorraline teadur (1,00)
01.04.2005–30.09.2006   
Tartu Ülikool, Arstiteaduskond, Mikrobioloogia instituut, laborant (0,75)
 
 
Haridustee
2006–2011   
Tartu Ülikool, meditsiiniline viroloogia, Ph.D
2004–2006   
Tartu Ülikool, biomeditsiin, M.Sc
2000–2004   
Tartu Ülikool, geenitehnoloogia, molekulaardiagnostika ja transgeense-tehnoloogia eriala, B.Sc

Kvalifikatsioon

Teaduskraadid
Radko Avi, Doctor's Degree, 2011, (sup) Irja Lutsar, Natural polymorphisms and transmitted drug resistance in Estonian HIV-1 CRF06_cpx and its recombinant viruses, University of Tartu.
Radko Avi, Research Master's Degree, 2006, (sup) Irja Lutsar, Looduslikud resistentsusmutatsioonid Eestis levivatel HI-viirustel, University of Tartu, Faculty of Medicine.
 
 

Lõppenud projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

1.1. Scholarly articles indexed by Web of Science Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index and/or indexed by Scopus (excluding chapters in books)
 
Soodla, Pilleriin; Huik, Kristi; Pauskar, Merit; Cuypers, Lize; Van Laethem, Kristel; Rajasaar, Heli; Kallas, Eveli; Lepa, Helen; Velts-Lindh, Anna; Jõgeda, Ene-Ly; Lutsar, Irja; Avi, Radko (2019). Stable level of HIV transmitted drug resistance in Estonia despite significant scale-up of antiretroviral therapy. Infection, Genetics and Evolution, 75, 103901−103901.10.1016/j.meegid.2019.05.019.
 
Huik, Kristi; Soodla, Pilleriin; Pauskar, Merit; Owen, S. Michele; Luo, Wei; Murphy, Gary; Jogeda, Ene-Ly; Kallas, Eveli; Rajasaar, Heli; Avi, Radko; Masciotra, Silvina; Lutsar, Irja; Del Amo, Julia; Meyer, Laurence; Bucher, Heiner C.; Chene, Genevieve; Hamouda, Osamah; Pillay, Deenan; Prins, Maria; Rosinska, Magda ... Scott, Martin (2019). The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx. PLOS ONE, 14 (5), ARTN e0217048.10.1371/journal.pone.0217048.
 
Soodla, Pilleriin; Huik, Kristi; Pauskar, Merit; Cuypers, Lize; Van Laethem, Kristel; Rajasaar, Heli; Kallas, Eveli; Lepa, Helen; Velts-Lindh, Anna; Jõgeda, Ene-Ly; Lutsar, Irja; Avi, Radko; (2019). Stable level of HIV transmitted drug resistance in Estonia despite significant scale-up of antiretroviral therapy. Infection, Genetics and Evolution, 75, 103901.10.1016/j.meegid.2019.05.019.
 
Jõgeda, E-L; Avi, R; Pauskar, M; Kallas, E; Karki, T; Des Jarlais, D; Uusküla, A; Toompere, K; Lutsar, I; Huik, K (2018). Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. Journal of Medical Virology, 90 (11), 1779−1783.10.1002/jmv.25258.
 
Jogeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Karki, Tonis; Jarlais, Don Des; Uuskula, Anneli; Lutsar, Irja; Avi, Radko (2017). Prevalence and Genotypes of GBV-C and Its Associations With HIV Infection Among Persons Who Inject Drugs in Eastern Europe. Journal of Medical Virology, 89 (4), 632−638.10.1002/jmv.24683.
 
Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLOS ONE, 11 (6), e0156850−e0156850.10.1371/journal.pone.0156850.
 
Avi, Radko; Pauskar, Merit; Karki, Tõnis; Kallas, Eveli; Jõgeda, Ene-Ly; Margus, Tõnu; Huik, Kristi; Lutsar, Irja (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology, 88 (3), 448−454.10.1002/jmv.24361.
 
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi (2016). Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection, Genetics and Evolution, 43, 83−85.10.1016/j.meegid.2016.05.022.
 
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 205 (3), 231−239.10.1007/s00430-015-0444-8.
 
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral immunology, 0−0.vim.2016.0057.
 
Soodla, P.; Rajasaar, H.; Avi, R.; Zilmer, K.; Kink, K.; Novikova, L.; Huik, K.; Maimets, M.; Lutsar, I. (2015). Design and structure of the Estonian HIV Cohort Study (E-HIV). Infectious Diseases, 47 (11), 768−675.10.3109/23744235.2015.1061203.
 
Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda, E.-L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection, Genetics and Evolution, 30, 175−180.10.1016/j.meegid.2014.12.023.
 
Rhee, S.-Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M.-L. ... Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLOS Medicine, 12 (4), e1001810.10.1371/journal.pmed.1001810.
 
Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66 (3), 239−244.10.1097/QAI.0000000000000127.
 
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Kallas, E; Jõgeda, EL; Krispin, T; Lutsar, I (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. Aids Research and Human Retroviruses, 30 (3), 278−283.10.1089/aid.2012.0357.
 
Huik, K; Avi, R; Pauskar, M; Kallas, E; Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection, Genetics and Evolution, 20, 78−82.10.1016/j.meegid.2013.08.008.
 
Huik, K; Avi, R; Carrillo, A; Harper, N; Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLOS ONE, 8 (7), e70561.10.1371/journal.pone.0070561.
 
Laisaar, K.-T.; Avi, R.; Dehovitz, J.; Uusküla, A. (2011). Estonia at the Threshold of the Fourth Decade of the AIDS Era in Europe. Aids Research and Human Retroviruses, 27 (8), 841−851.10.1089/aid.2010.0223.
 
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2011). Emerging Transmitted Drug Resistance in Treatment Naive Human Immunodeficiency Virus - 1 CRF06_cpx Infected Patients in Estonia. Scandinavian Journal of Infectious Diseases, 43 (2), 122−128.
 
Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2010). Characterization of Integrase Region Polymorphisms in HIV-1 CRF06_cpx Viruses in Treatment Naïve Patients in Estonia. Aids Research and Human Retroviruses, 26 (10), 1109−1113.10.1089/aid.2010.0097.
 
Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730−739.
 
Avi, R; Huik, K; Sadam, M; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2009). Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus-1 CRF06_cpx in Treatment-Naive Patients in Estonia. Journal of Medical Virology, 81 (6), 953−958.10.1002/jmv.21482.
2.4. University textbooks
 
Lutsar, Irja; Mändar, Reet; Mikelsaar, Marika; Karki, Tõnis; Brilene, Tatjana; Kõljalg, Siiri; Meriste, Sirli; Sepp, Epp; Avi, Radko; Truusalu, Kai; Parm, Ülle (2017). Meditsiiniline Mikrobioloogia. Üldmikrobioloogia. Tartu: TÜ kirjastus.
3.1. Articles/chapters in books published by the publishers listed in Annex (including collections indexed by the Thomson Reuters Book Citation Index, Thomson Reuters Conference Proceedings Citation Index, Scopus)
 
Rätsep, M.; Hütt, P.; Avi, R.; Utt, M.; Songisepp, E. (2011). Antimicrobial properties of Lactobacillus plantarum Tensia (DSM 21380) and Inducia (DSM 21379). In: Mendez-Vilas, A. (Ed.). Science and Technology against Microbial Pathogens. Research, Development and Evaluation. (393−397).. World Scientific Publ Co Pte Ltd.
3.5. Articles/presentations published in local conference proceedings
 
Tamman, S; Denks, K; Huik, K; Parm, Ü; Avi, R; Lutsar, I. (2008). Klebsiella pneumoniae genotüpiseerimine multiensüüm-multipleks amplified fragmrnt length polymorphism PCR (AFLP-PCR) meetodil. Eesti Arst.
5.1. Conference abstracts indexed by Thomson Reuters Web of Science
 
Avi1, R.; Pauskar2, M.; Rajasaar3, H.; Kallas4, E.; Jogeda5, E.; Soodla6, P.; Lutsar7, I. (2017). VIROLOGICAL RESPONSE TO ANTIRETROVIRAL TREATMENT IN AN EASTERN EUROPEAN COHORT STUDY. CROI Foundation/IAS–USA,.
 
Denks, K.; Huik, K.; Avi, R.; Sadam, M.; Krispin, T.; Lutsar, I. (2007). GB virus C infection among HIV-positive patients in Estonia. International Journal of Antimicrobial Agents, 29 (3), S155−S155.
 
Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Paap, P.; Smidt, J.; Ainsalu, K.; Krispin, T.; Lutsar, I (2007). The coexistence of secondary PR mutations M36I, K20I and L63H predominates in CRF06_cpx and its next generation recombinant virusese circulating in Estonian treatment naive patients. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 29. S549−S549.
5.2. Conference abstracts that do not belong to section 5.1
 
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Jarlais, Don Des; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi; (2015). HTLV-1/2 is rare among Eastern-European intravenous drug users (IDUs). Retrovirology, 12, P79−P79.10.1186/1742-4690-12-S1-P79.
 
Avi, Radko; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Šmidt, Jelena; Novikova, Lilia; Semjonova, Svetlana; Lutsar, Irja. (2013). Substitutions in RNaseH and Connection domain of HIV-1 CRF06_cpx viruses in treatment naive and treatment experienced populations. 11th European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance; Rome; 20-22 March 2013. 35−35.
 
Jõgeda, Ene-Ly; Huik, Kristi; Pauskar, Merit; Kallas, Eveli; Krispin, Tõnu; Karki, Tõnis; Marsh, Kristina; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja. (2013). The prevalence of GBV-C and its associations with HIV infection among Estonian intravenous drug users. Reviews in Antiviral Therapy Infectious Diseases: 11th European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance; Rome; 20-22 March 2013. 46−47.
 
Avi, R.; Huik, K.; Pauskar, M., Lutsar, I.; Vandamme, A.; Abecasis, A. (2012). The population dynamics of the HIV-1 epidemic in Estonia through virus genetic analysis and national case recording. 17th International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology, 27-31 August 2012 Belgrade Serbia.
 
Uibopuu, H.; Huik, K.; Avi, R.; Pauskar, M.; Kallas, E.; Karki, T.; Krispin, T.; Kool, P.; Schmidt, J.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Lutsar, I. (2012). Viral tropism of HIV-1 CRF06_cpx and its association with CCR5 haplotypes. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.
 
Pauskar, M.; Avi, R.; Huik, K.; Ustina, V.; Jõgeda, E.; Kallas, E.; Karki, T.; Krispin, T.; Lutsar, I. (2012). Transmitted drug resistance is 4.5% in newly diagnosed mainly HIV-1 CRF06_cpx infected patients in Estonia in 2010. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.
 
Avi, R.; Huik, K.; Pauskar, M.; Kallas, E.; Karki, T.; Krispin, T.; Ainsalu, K.; Semjonova, S.; Kool, P.; Novikova, L.; Schmidt, J.; Lutsar, I. (2012). The pattern of drug resistance mutations in HIV-1 CRF06_cpx viruses failing the first-line NNRTI+2NRTI antiretroviral therapy. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.
 
Kallas, E.; Avi, R.; Huik, K.; Pauskar, M.; Ustina, V.; Karki, T.; Krispin, T.; Ainsalu, K.; Semjonova, S.; Kool, P.; Novikova, L.; Schmidt, J.; Lutsar, I. (2012). HIV Type-1 CRF06_cpx P(T/S)AP Late Domain duplications are outselected among treatment experienced compared to treatment naïve patients. Reviews in Antiviral Therapy & Infectious Diseases. ,.
 
Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Denks, K.; Krispin, T.; Ustina, V.; Rüütel, K.; Uusküla, A.; Murphy, G.; Lutsar, I. (2009). Performance of the BED-CEIA in population infected with HIV1 recombinant viruses CRF06cpx and CRF06A. Clinical Microbiology and Infection: 19th European Congress of Clinical Microbiology and Infectious Diseases Helsinki, Finland, 16 - 19 May 2009.
 
Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Albert, J.; Lutsar, I. (2008). Drug Resistance Mutations in HIV-1 CRF06_cpx Viruses Isolated from Treatment Naïve and Experienced Patients. European Journal of Medical Research: 19th European Students’ Conference; Berlin; 28 September - 3 October 2008.
 
Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Drug Resistance Mutations and Genetic Barrier for Drug Resistance Development in Estonian HIV-1 CRF06_cpx Integrase Sequences. 14th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology; Cape Town, South Africa; 1-5 September 2008.
 
Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Paap, P.; Ainsalu, K.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Natural polymorphisms associated with integrase inhibitor drug resistance in Estonian HIV-1 CRF06_cpx strains. 18th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19.04-22.04.2008.
 
Sadam, M.; Karki, T.; Huik, K.; Avi, R.; Rüütel, K.; Uusküla, A.; Lutsar, I (2008). CCL3L1 Variable Gene Copy Number Influence on the Susceptibility to HIV-1/AIDS Among Estonian Intravenous Drug User. The 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 03.02-06.02.2008.
24.03.2020

Search project

  • {{item.Name}}
Institution is projects' financier   Institution is projects' executor  
  • {{searchListItem.Name}}
All   Projects   Master projects   Subprojects  
New Frascati (2015)
Old and new Frascati
All
Ongoing
Finished
Beginning
Fuzzy
Precise
Simple Search Clear
  • Found 8 results
ProgramTypeNumberNameProject startProject endPrincipal investigatorInstitutionFinancing
ETFETF8415Impact of CCR5 and CCL3L1 genetic polymorphism and their expression modulating viruses on the immune activation of antiretrovirus treatment positive HIV-patients.01.01.201031.12.2013Tõnis KarkiUniversity of Tartu, Faculty of Medicine61 354,00 EUR
ETFETF8856The impact of regulatory region methylation of CCR5 and its signaling pathway associated genes on the HIV seropositivity in the caucasian intravenous drug users population01.01.201131.12.2013Silver TürkUniversity of Tartu, Faculty of Medicine25 200,00 EUR
SFSF0182726s06HIV infection in Estonia: molecular and clinical implications of host and virus interactions.01.01.200631.12.2011Irja LutsarUniversity of Tartu, Faculty of Medicine372 766,67 EUR
SFSF0180004s12Infection and immunocompromised host - from mechanisms to translation into clinical practice01.01.201231.12.2014Irja LutsarUniversity of Tartu, Faculty of Medicine349 080,00 EUR
IUTIUT34-24Management of infections in the immunocompromised host – from bench to bedside01.01.201531.12.2020Irja LutsarUniversity of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine698 400,00 EUR
ETFETF6041Detection of conserved sequence motifs in eukaryotic genomes using comparative genomics approach01.01.200531.12.2006Maido RemmEstonian Biocentre12 910,15 EUR
ETFETF8004Influence of host genetic polymorphisms on evolution of HIV monophyletic population01.01.200931.12.2012Tõnu KrispinUniversity of Tartu, Faculty of Medicine80 989,62 EUR
PUT; PUT_OPPUT1580The impact of virome and human endogenous retroviruses on immunologic recovery during suppressive combination antiretroviral therapy in people who inject drugs01.01.201731.12.2020Radko AviUniversity of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine280 320,00 EUR